Presenters: Celeste Lindley, PharmD; Steven M. Grundberg, MD; John D. Hainsworth, MD; Stephen L. Huber, MS, RPh
Learn about determining the emetogenic potential for chemotherapy agents; review new class system and algorithm for determining emetogenic potential of combo chemotherapy regimens. Discussions include the rationale for stratification of antiemetic dosage based on the emetogenicicity of the chemotherapy regimen; appreciating the cost and revenue comparisons for the 5HT3 antiemetics based on dosing considerations and identifing strategies for enhancing the antiemetics in a variety of practice settings.
|